CLINICAL_TRIALS
trial_result
· 2024-09-04
Clinical Trial Update: Safety & Efficacy of Encapsulated Allogeneic FVIII Cell Therapy in Haemophilia A [Phase 1, Phase 2]
Summary
Phase 1/2 trial evaluating an encapsulated allogeneic FVIII cell therapy for Hemophilia A was terminated, with results posted in September 2024.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Eli Lilly and Company | Conditions: Hemophilia A | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-09-04